Orion Portfolio Solutions LLC Makes New $116,000 Investment in Allergan plc (NYSE:AGN)
Orion Portfolio Solutions LLC bought a new stake in Allergan plc (NYSE:AGN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 609 shares of the company’s stock, valued at approximately $116,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in shares of Allergan by 8.0% in the 4th quarter. AQR Capital Management LLC now owns 432,114 shares of the company’s stock valued at $82,608,000 after purchasing an additional 32,169 shares during the period. Caisse DE Depot ET Placement DU Quebec increased its holdings in shares of Allergan by 11.8% in the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 640,405 shares of the company’s stock worth $122,426,000 after purchasing an additional 67,800 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Allergan in the 4th quarter worth $12,617,000. UBS Asset Management Americas Inc. increased its holdings in shares of Allergan by 1.1% in the 4th quarter. UBS Asset Management Americas Inc. now owns 1,319,718 shares of the company’s stock worth $252,290,000 after purchasing an additional 14,465 shares in the last quarter. Finally, TIG Advisors LLC increased its holdings in shares of Allergan by 7.2% in the 4th quarter. TIG Advisors LLC now owns 2,223,155 shares of the company’s stock worth $425,001,000 after purchasing an additional 149,353 shares in the last quarter. Institutional investors own 83.91% of the company’s stock.
A number of analysts have commented on AGN shares. Wells Fargo & Co lowered Allergan from an “overweight” rating to an “equal weight” rating and set a $198.00 target price for the company. in a report on Wednesday, January 22nd. ValuEngine raised Allergan from a “sell” rating to a “hold” rating in a report on Tuesday. Cfra lowered Allergan from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, SunTrust Banks lifted their price objective on Allergan from $194.00 to $202.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Fifteen investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $178.29.
Allergan (NYSE:AGN) last released its earnings results on Monday, February 10th. The company reported $5.22 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.57 by $0.65. The company had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.09 billion. Allergan had a positive return on equity of 9.82% and a negative net margin of 32.76%. Allergan’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the business earned $4.29 earnings per share. As a group, sell-side analysts predict that Allergan plc will post 17.58 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Investors of record on Thursday, April 16th will be given a dividend of $0.74 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.96 annualized dividend and a yield of 1.75%. Allergan’s dividend payout ratio (DPR) is presently 16.78%.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Recommended Story: Understanding each part of a balance sheet
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.